SAGE Therapeutics to Present at 33rd Annual J.P. Morgan Healthcare Conference
January 05, 2015 06:30 ET
|
SAGE Therapeutics
CAMBRIDGE, Mass., Jan. 5, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central...
SAGE Therapeutics Added to NASDAQ Biotechnology Index
December 17, 2014 06:30 ET
|
SAGE Therapeutics
CAMBRIDGE, Mass., Dec. 17, 2014 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central...
SAGE Therapeutics Reports Third Quarter 2014 Results
November 11, 2014 06:30 ET
|
SAGE Therapeutics
CAMBRIDGE, Mass., Nov. 11, 2014 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central...
SAGE Therapeutics Reports Positive Top-Line Phase 2 Data of SAGE-547 in Patients With Super-Refractory Status Epilepticus
November 10, 2014 06:30 ET
|
SAGE Therapeutics
SAGE-547 Met Primary and Secondary Efficacy and Safety Endpoint Targets
Overall Response Rate of 73 Percent Reported with No Drug-Related SAEs
CAMBRIDGE, Mass., Nov. 10, 2014 (GLOBE NEWSWIRE)...
SAGE Therapeutics Announces Six Scientific Presentations at Neuroscience 2014, the Society for Neuroscience's 44th Annual Meeting
November 07, 2014 06:30 ET
|
SAGE Therapeutics
CAMBRIDGE, Mass., Nov. 7, 2014 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central...
SAGE to Present at Credit Suisse 23rd Annual Healthcare Conference
November 05, 2014 06:30 ET
|
SAGE Therapeutics
CAMBRIDGE, Mass., Nov. 5, 2014 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central...
First Evaluation of SAGE-547 to Treat Super-Refractory Status Epilepticus in Children Published in Annals of Neurology
November 03, 2014 06:30 ET
|
SAGE Therapeutics
CAMBRIDGE, Mass., Nov. 3, 2014 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE) today announced that SAGE-547, an allosteric modulator of GABAA receptors, was used to treat super-refractory status...
SAGE Therapeutics Initiates Exploratory Study of SAGE-547 in Essential Tremor
October 23, 2014 06:30 ET
|
SAGE Therapeutics
CAMBRIDGE, Mass., Oct. 23, 2014 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE) today announced dose initiation of the first patient in a single-center Phase 2a clinical trial of SAGE-547, an...
SAGE Therapeutics to Participate in the 2014 Leerink Partners Rare Disease Roundtable
September 25, 2014 06:30 ET
|
SAGE Therapeutics
CAMBRIDGE, Mass., Sept. 25, 2014 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central...
SAGE Therapeutics Appoints Michael F. Cola to the Company's Board of Directors
September 16, 2014 06:30 ET
|
SAGE Therapeutics
CAMBRIDGE, Mass., Sept. 16, 2014 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central...